Medacta announces the results of today's Annual General Meeting

Media Release   

Medacta announces the results of today's Annual General Meeting 

• All proposals of the Board of Directors were approved
• The distribution of around CHF 13.7 million, or CHF 0.69 per share, was approved
• Dr. Alberto Siccardi as Chair of the Board of Directors and all other Board members standing for re-election were confirmed  

CASTEL SAN PIETRO, Switzerland, 7 May 2025 – Medacta Group SA (“Medacta”, SIX:MOVE) today announced that its shareholders approved all proposals made by the Board of Directors at today's Annual General Meeting (“AGM”) .

Today's AGM was held with the physical participation of shareholders and took place at the Group premises in Via alla Rossa 6, Rancate - Switzerland. A total  of 17,881,923 shares were represented, either by attending shareholders or by third-party proxy and by the independent proxy, corresponding to approximately 89.41% of Medacta's share capital.

Shareholders approved the distribution of around CHF 13.7 million, or CHF 0.69 per share, half of it to be distributed as dividend out of available earnings and half of it to be distributed out of accumulated reserves from capital contribution.

Alberto Siccardi, Maria Luisa Siccardi Tonolli, Victor Balli, Riccardo Braglia and Philippe Weber were each re-elected as members of the Board of Directors for one-year term of office and Alberto Siccardi was re-elected as chairman of the Board. Medacta's shareholders also re-elected Philippe Weber and Riccardo Braglia as members of the Remuneration Committee for a term of one year.

Further proposals by the Board of Directors that were approved at today's AGM included the following:

• The approval of the Management Report, the Annual Statutory Financial Statements and the Consolidated Financial Statements for the financial year 2024;
• The approval of the 2024 Report on non-financial matters;
• The approval of the Remuneration Report for the financial year 2024;
• The approval of the appropriation of available earnings as of 31 December 2024 of Medacta Group SA for the financial year 2024;
• The discharge of the members of the Board of Directors and the Executive Management;
• The re-election of the independent proxy and the auditors;
• The maximum aggregate compensations of the Board of Directors and the members of the Executive Management;

The minutes of the 2025 AGM will be available in due course at:
https://www.medacta.com/EN/agm

Contact

Medacta International
Anja Pomrehn
Group VP Sustainability and Investor & Media Relations
Telephone: +41 91 696 14 95
Email: pomrehn@medacta.ch

About Medacta
Medacta is a global key player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta’s innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 60 countries. Follow us on Medacta.com, Medacta TV, YouTube, LinkedIn and X.